Drugs / 68Ga-NOTA-AE105
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02437539 | May → Aug 2015 | breast cancer, prostate cancer, urinary bladder cancer | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT03307460 | Nov 2017 → Oct 2019 | prostate cancer | Rigshospitalet, Denmark | Unknown | No outcome recorded |
| Phase 2 | NCT03278275 | Nov 2017 → Jul 2021 | neuroendocrine neoplasm | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 2 | NCT02964988 | Jan 2017 → Oct 2019 | metastatic carcinoma in the bone, metastatic prostate carcinoma | Rigshospitalet, Denmark | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02945826 | Jan 2017 → Dec 2020 | glioblastoma | Rigshospitalet, Denmark | Unknown | No outcome recorded |
| Phase 2 | NCT02805608 | Sep 2016 → Jan 2019 | urinary bladder neoplasm | Rigshospitalet, Denmark | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2024-11-07 | Curasight | Results Clinical phase II trial of uPAR-PET in brain cancer patients published; data supports development of uTREAT for brain cancer curasight.com ↗
Almost all (94%) of the grade 4 gliomas (glioblastomas) were uPAR-PET positive. |
| 2023-09-14 | Curasight | Results Positive results from the Phase II study of uTRACE in brain cancer presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague curasight.com ↗
The majority of the glioma patients displayed uPAR-positive tumors |
| 2023-06-29 | Curasight | Results Positive results in uPAR-PET/MR Phase II study in brain cancer curasight.com ↗
Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) announces today positive results from the investigator-initiated phase II study using uPAR-PET (uTRACE[®]) in primary brain cancer. |
| 2022-01-27 | Curasight | Results Phase II study of uPAR-PET in neuroendocrine tumor patients demonstrates strong prognostic value and supports potential future use of uPAR-targeted radionuclide therapy curasight.com ↗
The study demonstrates strong prognostic value and that uPAR is expressed in the majority of neuroendocrine tumor patients. |
| 2021-12-09 | Curasight | Results Phase II study demonstrates prognostic value of uPAR-PET in head and neck cancer patients curasight.com ↗
The main finding was that patients with high uptake on uPAR-PET compared to those with a low uptake had an 8.5-fold poorer prognosis regarding relapse-free survival. |
| 2021-02-26 | Curasight | Results Article from Phase II study in prostate cancer now published in the March issue of Journal of Nuclear Medicine and highlighted as best clinical investigation article curasight.com ↗
SUV*) measurements from uPAR PET in primary tumors as delineated by mpMRI showed a significant correlation with Gleason score, and tumor SUVmax was able to discriminate between low-risk and intermediate-risk Gleason score profiles with high diagnostic accuracy. |
| 2020-12-21 | Curasight | Results Results from Phase II study in prostate cancer to be published in the Journal of Nuclear Medicine curasight.com ↗
SUV*) measurements from uPAR PET in primary tumors as delineated by mpMRI showed a significant correlation with Gleason score, and tumor SUVmax was able to discriminate between low-risk and intermediate risk Gleason score profiles with high diagnostic accuracy. |
All press releases naming this drug 7 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-NOTA-AE105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02805608 ↗ |
| Modality | Peptide | “a linear, high-affinity uPAR peptide antagonist, AE105” PMID 22213823 ↗ Jan 2012 |
| Route | Intravenous | “One injection intravenously of 68Ga-NOTA-AE105” NCT02805608 ↗ |